Biogen (BIIB) falls as earnings, revenue misses consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024 4:06 PM ESTFriedreichs ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients
CAMBRIDGE, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreichs... More
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
February 9, 2024 10:00 AM ESTNew partnership model leverages Aptar Digital Healths capabilities to support the development and operation of new and existing digital health solutions globally Initial scope of multi-year agreement covers several indications in neurology and immunology across 15 countries
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Digital Health, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and... More
